Kate Kennedy
Nurse Practitioner · Bellevue, WANPI 1245309442
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,543 of the $63,149 with a category attached, or 69.0%. AbbVie accounts for 65.6% of it on its own, with 28 other manufacturers making up the rest. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $177.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$41K
- Lundbeck LLC$13K
- Pfizer$3K
- Teva Pharmaceuticals USA, Inc.$678
- Lilly USA, LLC$654
- Argenx US, Inc.$569
- plus $3K from 23 others
What the payments were for
- Consulting fees$8,12613%
- Speaking & faculty fees$43,54369%
- Travel & lodging$2,7944%
- Food & beverage$8,68614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 140 | $41,457 |
| Lundbeck LLC | 35 | $13,380 |
| Pfizer | 14 | $3,349 |
| Teva Pharmaceuticals USA, Inc. | 23 | $678 |
| Lilly USA, LLC | 21 | $654 |
| Argenx US, Inc. | 12 | $569 |
| UCB, Inc. | 11 | $415 |
| Impel Pharmaceuticals Inc. | 11 | $365 |
| Bristol Myers Squibb | 19 | $334 |
| Tonix Medicines, Inc. | 4 | $272 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $205 |
| Biohaven Pharmaceuticals, Inc. | 7 | $202 |
| SK Life Science, Inc. | 5 | $154 |
| Neurelis, Inc. | 8 | $143 |
| Upsher-smith Laboratories LLC | 6 | $142 |
| Eisai Inc. | 4 | $110 |
| EMD Serono, Inc. | 3 | $97 |
| Amgen | 2 | $97 |
| Alnylam Pharmaceuticals Inc. | 3 | $75 |
| Amneal Pharmaceuticals LLC | 5 | $69 |
| Novartis | 3 | $66 |
| Acadia Pharmaceuticals Inc | 2 | $55 |
| Acorda Therapeutics, Inc | 2 | $52 |
| Biogen | 2 | $45 |
| Boston Scientific | 2 | $45 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| CSL Behring | 1 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,149 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $60,289 |
| Nurtec OdtRimegepant Sulfate | 35 | $48,285 |
| Emgality PenGalcanezumab-Gnlm | 57 | $47,143 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $45,400 |
| UbrelvyUbrogepant | 21 | $27,196 |
| ImitrexSumatriptan Succinate | 13 | $25,171 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $18,631 |
| QuliptaAtogepant | 14 | $17,316 |
| Sumatriptan Succinate | 121 | $13,376 |
| Ajovy SyringeFremanezumab-Vfrm | 15 | $12,870 |
| Topiramate ErTopiramate | 11 | $12,798 |
| BelbucaBuprenorphine Hcl | 14 | $9,223 |
| ReyvowLasmiditan Succinate | 11 | $8,399 |
| Zolmitriptan OdtZolmitriptan | 14 | $5,485 |
| Dimethyl Fumarate | 13 | $2,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $3,349 | $48,28535 claims |
| AbbVieUbrelvy, Qulipta | $41,457 | $44,51235 claims |
| Lilly USA, LLCReyvow | $654 | $8,39911 claims |
| Upsher-smith Laboratories LLCTopiramate | $142 | $79966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Bellevue
- Amaris MurphyBellevue$146K
- Tyler KuhkBellevue$33K
- Wenting JiangBellevue$5K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Vicki HainesPasco$57K
- Jessica ArmitageSumner$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.